Buprenorphine in primary care: Risk factors for treatment injection and implications for clinical management

Drug and Alcohol Dependence

Volumn 97, Issue 1-2, 2008, Pages 105-113

  Roux, Perrine ^a,b,c   Villes, Virgine ^a,b,c   Blanche, Jerome ^a,b,c   Bry, Didier ^e   Spire, Bruno ^a,b,c   Feroni, Isabelle ^a,c,d   Carrieri, M Patrizia ^a,b,c  

^a INSERM   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^d UNIVERSITÉ CÔTE D'AZUR   (France)

^e Réseau de santé toxicomanie du Vaucluse Retox 84   (France)

Author keywords

Buprenorphine; Diversion; Dosage; Injection; Opioid substitution treatment; Primary care

Indexed keywords

BUPRENORPHINE;

ADULT; ARTICLE; COMORBIDITY; CONFIDENCE INTERVAL; DRUG DEPENDENCE; DRUG INTOXICATION; FEMALE; FRANCE; HEALTH SURVEY; HUMAN; LOGISTIC REGRESSION ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK FACTOR; SOCIAL ASPECT; SUICIDAL IDEATION; SUICIDE ATTEMPT;

EID: 46649090296     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2008.03.025     Document Type: Article

References (56)

1. Allen J.P., Litten R.Z., Fertig J.B., and Babor T. A review of research on the Alcohol Use Disorders Identification Test (AUDIT). Alcohol Clin. Exp. Res. 21 4 (1997) 613-619
2. Auriacombe M., Franques P., and Tignol J. Deaths attributable to methadone vs buprenorphine in France. JAMA 285 1 (2001) 45
3. Avants S.K., Margolin A., and McKee S. A path analysis of cognitive, affective, and behavioral predictors of treatment response in a methadone maintenance program. J. Subst. Abus. 11 3 (2000) 215-230
4. Barrau K., Thirion X., Micallef J., Chuniaud-Louche C., Bellemin B., and San Marco J.L. Comparison of methadone and high dosage buprenorphine users in French care centres. Addiction 96 10 (2001) 1433-1441
5. Berson A., Fau D., Fornacciari R., Degove-Goddard P., Sutton A., Descatoire V., Haouzi D., Letteron P., Moreau A., Feldmann G., and Pessayre D. Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation. J. Hepatol. 34 2 (2001) 261-269
6. Berson A., Gervais A., Cazals D., Boyer N., Durand F., Bernuau J., Marcellin P., Degott C., Valla D., and Pessayre D. Hepatitis after intravenous buprenorphine misuse in heroin addicts. J. Hepatol. 34 2 (2001) 346-350
7. Blanchon T., Boissonnas A., Vareseon I., and Vidal-Trecan G. Homelessness and high-dosage buprenorphine misuse. Subst. Use Misuse 38 3-6 (2003) 429-442
8. Brewster D., Humphrey M.J., and McLeavy M.A. The systemic bioavailability of buprenorphine by various routes of administration. J. Pharm. Pharmacol. 33 8 (1981) 500-506
9. Byrne A., and Wodak A. Data do not support buprenorphine as a first-line treatment for addiction. Am. J. Psychiatry 164 11 (2007) 1757 author reply 1757-8
10. Caplehorn J.R., and Bell J. Methadone dosage and retention of patients in maintenance treatment. Med. J. Aust. 154 3 (1991) 195-199
11. Carlin J.B., Wolfe R., Coffey C., and Patton G.C. Analysis of binary outcomes in longitudinal studies using weighted estimating equations and discrete-time survival methods: prevalence and incidence of smoking in an adolescent cohort. Stat. Med. 18 19 (1999) 2655-2679
12. Carrieri M.P., Amass L., Lucas G.M., Vlahov D., Wodak A., and Woody G.E. Buprenorphine use: the international experience. Clin. Infect. Dis. 43 Suppl 4 (2006) S197-S215
13. Carrieri M.P., Chesney M.A., Spire B., Loundou A., Sobel A., Lepeu G., and Moatti J.P. Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. Int. J. Behav. Med. 10 1 (2003) 1-14
14. Courty P. High dosage buprenorphine and injection practices. A study of 303 patients. Ann. Med. Interne (Paris) 154 Spec No 1 (2003) S35-S45
15. Decocq G., Fremaux D., Smail A., Compagnon M., and Andrejak M. Local complications after intravenous injection of dissolved tablets of buprenorphine. Presse Med. 26 30 (1997) 1433
16. Del Giudice P. Cutaneous complications of intravenous drug abuse. Br. J. Dermatol. 150 1 (2004) 1-10
17. Duburcq A., Charpak Y., Blin P., and Madec L. Two years follow-up of a heroin users cohort treated with high dosage buprenorphine. Results of the SPESUB study (pharmacoepidemiologic follow-up of general practice Subutex). Rev. Epidemiol. Sante Publique 48 4 (2000) 363-373
18. Eap C.B., Felder C., Golay K.P., and Uehlinger C. Increase of oral methadone dose in methadone injecting patients: a pilot study. J. Addict. Dis. 22 3 (2003) 7-17
19. Faggiano F., Vigna-Taglianti F., Versino E., and Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst. Rev. 3 (2003) CD002208
20. Feroni I., Aubisson S., Bouhnik A.D., Paraponaris A., Masut A., Coudert C., and Obadia Y. Collaboration between general practitioners and pharmacists in the management of patients on high-dosage buprenorphine treatment. Prescribers' practices. Presse Med. 34 17 (2005) 1213-1219
21. Feroni I., Peretti-Watel P., Masut A., Coudert C., Paraponaris A., and Obadia Y. French general practitioners' prescribing high-dosage buprenorphine maintenance treatment: is the existing training (good) enough?. Addict. Behav. 30 1 (2005) 187-191
22. Fuhrer R., Rouillon F., and Lellouch J. Diagnostic reliability among French psychiatrists using DSM-III criteria. Acta Psychiatr. Scand. 73 1 (1986) 12-16
23. Gerra G., Borella F., Zaimovic A., Moi G., Bussandri M., Bubici C., and Bertacca S. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend. 75 1 (2004) 37-45
24. Goldstein A., Hansteen R.W., and Horns W.H. Control of methadone dosage by patients. JAMA 234 7 (1975) 734-737
25. Gossop M., Marsden J., Stewart D., and Rolfe A. Treatment retention and 1 year outcomes for residential programmes in England. Drug Alcohol Depend. 57 2 (1999) 89-98
26. Gouny P., Gaitz J.P., and Vayssairat M. Acute hand ischemia secondary to intraarterial buprenorphine injection: treatment with iloprost and dextran-40--a case report. Angiology 50 7 (1999) 605-606
27. Guichard A., Lert F., Brodeur J.M., and Richard L. Buprenorphine substitution treatment in France: drug users' views of the doctor-user relationship. Soc. Sci. Med. 64 12 (2007) 2578-2593
28. Johnson R.E., Strain E.C., and Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend. 70 2 Suppl (2003) S59-S77
29. Kakko J., Gronbladh L., Svanborg K.D., von Wachenfeldt J., Ruck C., Rawlings B., Nilsson L.H., and Heilig M. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am. J. Psychiatry 164 5 (2007) 797-803
30. Latkin C.A., Vlahov D., and Anthony J.C. Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. Addiction 88 4 (1993) 517-526
31. Leroux I., and Morin T. Facteurs de risque des épisodes dépressifs en population générale. Etudes et résultats (2006) 545
32. Loo H.W., Yam A.K., Tan T.C., Peng Y.P., and Teoh L.C. Severe upper limb complications from parenteral abuse of Subutex. Ann. Acad. Med. Singapore 34 9 (2005) 575-578
33. Lovejoy M., Rosenblum A., Magura S., Foote J., Handelsman L., and Stimmel B. Patients' perspective on the process of change in substance abuse treatment. J. Subst. Abus. Treat. 12 4 (1995) 269-282
34. Mayfield D., McLeod G., and Hall P. The CAGE questionnaire: validation of a new alcoholism screening instrument. Am. J. Psychiatry 131 10 (1974) 1121-1123
35. McGirr A., Renaud J., Seguin M., Alda M., Benkelfat C., Lesage A., and Turecki G. An examination of DSM-IV depressive symptoms and risk for suicide completion in major depressive disorder: a psychological autopsy study. J. Affect. Disord. 97 1-3 (2007) 203-209
36. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., Pettinati H., and Argeriou M. The fifth edition of the Addiction Severity Index. J. Subst. Abus. Treat. 9 3 (1992) 199-213
37. McLellan A.T., McKay J.R., Forman R., Cacciola J., and Kemp J. Reconsidering the evaluation of addiction treatment: from retrospective follow-up to concurrent recovery monitoring. Addiction 100 4 (2005) 447-458
38. Peles E., Schreiber S., Naumovsky Y., and Adelson M. Depression in methadone maintenance treatment patients: rate and risk factors. J. Affect. Disord. 99 1-3 (2007) 213-220
39. Potier A., Leclech C., Croue A., Chappard D., and Verret J.L. Necrotic livedo after injection of buprenorphine (Subutex). Ann. Dermatol. Venereol. 134 2 (2007) 148-150
40. Robles E., Miller F.B., Gilmore-Thomas K.K., and McMillan D.E. Implementation of a clinic policy of client-regulated methadone dosing. J. Subst. Abus. Treat. 20 3 (2001) 225-230 discussion 231
41. Sepulveda S., Dermine H., Mulot A., Villard M., and Haberer J.P. Acute pancreatitis after intravenous buprenorphine misuse in a heroin addict. Ann. Fr. Anesth. Reanim. 23 6 (2004) 658-659
42. Sigmon S.C., Moody D.E., Nuwayser E.S., and Bigelow G.E. An injection depot formulation of buprenorphine: extended bio-delivery and effects. Addiction 101 3 (2006) 420-432
43. Smyth B.P., Barry J., Lane A., Cotter M., O'Neill M., Quinn C., and Keenan E. In-patient treatment of opiate dependence: medium-term follow-up outcomes. Br. J. Psychiatry 187 (2005) 360-365
44. Sorensen J.L., and Copeland A.L. Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend. 59 1 (2000) 17-31
45. Spire B., Lucas G.M., and Carrieri M.P. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int. J. Drug Policy 18 4 (2007) 262-270
46. Strang J., Manning V., Mayet S., Ridge G., Best D., and Sheridan J. Does prescribing for opiate addiction change after national guidelines? Methadone and buprenorphine prescribing to opiate addicts by general practitioners and hospital doctors in England, 1995-2005. Addiction 102 5 (2007) 761-770
47. Thirion X., Lapierre V., Micallef J., Ronfle E., Masut A., Pradel V., Coudert C., Mabriez J.C., and Sanmarco J.L. Buprenorphine prescription by general practitioners in a French region. Drug Alcohol Depend. 65 2 (2002) 197-204
48. Trafton J.A., Minkel J., and Humphreys K. Determining effective methadone doses for individual opioid-dependent patients. PLoS Med. 3 3 (2006) e80
49. Van Den Berg C., Smit C., Van Brussel G., Coutinho R., and Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 102 9 (2007) 1454-1462
50. Varescon I., Vidal-Trecan G., Nabet N., and Boissonnas A. Buprenorphine abuse: high dose intravenous administration of buprenorphine. Encephale 28 5 Pt 1 (2002) 397-402
51. Vidal-Trecan G., Varescon I., Nabet N., and Boissonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend. 69 2 (2003) 175-181
52. Vignau J., Duhamel A., Catteau J., Legal G., Pho A.H., Grailles I., Beauvillain J., Petit P., Beauvillain P., and Parquet P.J. Practice-based buprenorphine maintenance treatment (BMT): how do French healthcare providers manage the opiate-addicted patients?. J. Subst. Abus. Treat. 21 3 (2001) 135-144
53. Walsh S.L., Preston K.L., Stitzer M.L., Cone E.J., and Bigelow G.E. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin. Pharmacol. Ther. 55 5 (1994) 569-580
54. Wesson D.R. Buprenorphine in the treatment of opiate dependence: its pharmacology and social context of use in the U.S. J. Psychoactive Drugs Suppl 2 (2004) 119-128
55. Wisniewski B., Perlemuter G., and Buffet C. Acute hepatitis following intravenous buprenorphine injection as a substitute drug in a drug-addict. Gastroenterol. Clin. Biol. 25 3 (2001) 328-329
56. Zeger S.L., and Liang K.Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42 1 (1986) 121-130